Xalacom: possibilities and advantages of the drug in the treatment of patients with glaucoma

Close metadata

Recommended articles:

The relationship between intraocular pressure and age-related variations in ocular rigidity. Russian Annals of Ophthalmology. 2024;(3):11-18

Comparative evaluation of transscleral laser exposure in anatomical experiment. Russian Annals of Ophthalmology. 2024;(3):19-26

Three-component tear substitute as preoperative support in glaucoma surgery. Russian Annals of Ophthalmology. 2024;(3):51-58

First experience of implantation of extended depth of focus intraocular lenses in patients with glaucoma. Russian Annals of Ophthalmology. 2024;(3):70-74

Application of artificial intelligence in glaucoma. Part 1. Neural networks and deep learning in glaucoma screening and diagnosis. Russian Annals of Ophthalmology. 2024;(3):82-87

Efficacy of drainage implants in combined cataract and glaucoma surgery. Russian Annals of Ophthalmology. 2024;(4):33-39

Application of artificial intelligence in glaucoma. Part 2. Neural networks and machine learning in the monitoring and treatment of glaucoma. Russian Annals of Ophthalmology. 2024;(4):80-85

Approaches for improvement of ocular surface condition in primary open-angle glaucoma. Russian Annals of Ophthalmology. 2024;(5):7-16

Perioperative prevention of bleeding in glaucoma surgery. Russian Annals of Ophthalmology. 2024;(5):118-124

Efficacy and safety of the fixed combination of dorzolamide/timolol (Dorzotimol) in primary open-angle glaucoma. Russian Annals of Ophthalmology. 2024;(5):125-129

The strategy of glaucoma therapy is aimed at preserving visual functions and ensuring an acceptable quality of life for patients. To achieve this strategic goal, clinicians in their practice use drugs that affect the main factor in the progression of the disease — intraocular pressure (IOP), aiming to reduce it to an individual target level. It is not always possible to achieve optimal IOP values with monotherapy. Many patients require a combination of drugs from different pharmacological groups. Xalacom is a fixed drug with good tolerability and t hypotensive effect. This review focuses on the benefits of this drug for the treatment of glaucoma.

Keywords:

glaucoma

hypertensive therapy

fixed combinations

timolol

latanoprost

Authors:

Alekseev I.B.

Russian Medical Academy of Continuous Professional Education

Volkova A.V.

Russian Medical Academy of Continuous Professional Education

Alekseeva L.I.

V.A. Nasonova Research Institute of Rheumatology

Received:

03.08.2022

Accepted:

16.08.2022

List of references:

World Health Organization. Blindness and vision impairment. Accessed 07.04.22 (In Russ.). https://www.who.int/ru/news-room/fact-sheets/detail/blindness-and-visual-impairment
Malihi M, Sit AJ. Effect of head and body position on intraocular pressure. Ophthalmology. 2012;119(5):987-991. https://doi.org/10.1016/j.ophtha.2011.11.024
Remington LA. Klinicheskaja anatomija i fiziologija zritel’noj sistemy [Clinical anatomy and physiology of the visual system]: Transl. from English. 3rd ed. M.: Publishing House «Gorodets»; 2020. (In Russ.).
Rukovodstvo po klinicheskoj oftal’mologii [Guide to clinical ophthalmology]. Eds Brovkina A.F., Astakhov Yu.S. M.: LLC «Publishing House «Medicinskoe informacionnoe agentstvo»; 2014. (In Russ.).
Bill A. Uveoscleral drainage of aqueous humor: physiology and pharmacology. Prog Clin Biol Res. 1989;312:417-427.
Nesterov AP. Glaukoma [Glaucoma]. M.: LLC «Publishing House «Medicinskoe informacionnoe agentstvo»; 2008;360. (In Russ.).
Kanski D. Klinicheskaja oftal’mologija: sistematizirovannyy podhod [Clinical ophthalmology: a systematic approach]: Transl. from English. 2nd ed. Ed. Erichev V.P. M.: Logosphere; 2009;944. (In Russ.).
Alm A, Kaufman PL, Kitazawa Y. Uveoscleral outflow: biology and clinical aspects. London: Mosby—Wolfe; 1998;99.
Egorov EA. Fixed combination of latanoprost and timolol in the treatment of glaucoma. RMZh. Klinicheskaya oftal’mologiya. 2015;15(2):73-77. (In Russ.).
European Glaucoma Society. Terminology and guidelines for glaucoma, 5th edition. European Glaucoma Society; 2020. Accessed 10.05.22. https://www.eugs.org.
Nacional’noe rukovodstvo po glaukome: dlyapraktikuyushchihvrachej [National guidelines for glaucoma: for practitioners]. Eds Egorov E.A., Erichev V.P. 4th ed., rev. and additional. M.: GEOTAR-Media; 2019. (In Russ.).
Mehran NA, Sinha S, Razeghinejad R. New glaucoma medications: latanoprostenebunod, netarsudil, and fixed combination netarsudil-latanoprost. Eye. 2020;34(1):72-88. https://doi.org/10.1038/s41433-019-0671-0
Kuroedov AV, Nagornova ZM, Tibieva ZU, Krinicyna EA, Sergeeva VM. Additive and combined glaucoma therapy: principes and practice. Rossijskij oftal’mologicheskij zhurnal. 2018;11(2):71-81. (In Russ.). https://doi.org/10.21516/2072-0076-2018-11-2-71-81
Andres-Guerrero V, Garcıa-Feijoo J, Konstas AG. Targeting schlemm’s canal in the medical therapy of glaucoma: current and future considerations. Advances in Therapy. 2017;34(5):1049-1069. https://doi.org/10.1007/s12325-017-0513-z
Grieshaber MC, Orguel S, Flammer J.Glaucoma therapy-state of the art. Basel; 2009;178.
Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost,and latanoprost. Current Medical Research and Opinion. 2006;22(5):971-976. https://doi.org/10.1185/030079906x104777
Kuroyedov AV, Brezhnev AYu, Lovpache JN, Petrov SYu, Tibieva ZU, Nagornova ZM, Krinitsyna EA, Sergeeva VM. The feasibility of adopting «stepwise» initial approaches in treatment of patients with different stages of glaucoma. Nacional’nyj zhurnal glaucoma. 2018;17(4):25-54. (In Russ.). https://doi.org/10.25700/NJG.2018.04.03
Patel SC, Spaeth GL. Compliance in patients prescribed eye drops for glaucoma. Ophthalmic Surgery. 1995;26(3):233-236. https://doi.org/10.3928/1542-8877-19950501-14
Singh K, Srivastava A. Medical management of glaucoma: Principles and practice. Indian Journal of Ophthalmology. 2011;59(1):88-92. https://doi.org/10.4103/0301-4738.73691
Kuroedov AV, Abysheva LD, Avdeev RV, Aleksandrov AS, et al. Cost-effectiveness ratio of local hypotensive treatment of patients with moderate and advanced primary open-angle glaucoma (a multicenter study). Rossijskij oftal’mologicheskij zhurnal. 2015;8(3):10-22. (In Russ.).
Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112(6):953-961. https://doi.org/10.1016/j.ophtha.2004.12.035
Konstas AG, Boboridis K, Tzetzi D, Kallinderis K, Jenkins JN, Stewart WC. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol. 2005;123(7):898-902. https://doi.org/10.1001/archopht.123.7.898
Dezii CM. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care. 2000;9(9 suppl):2-6.
Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail. 2003;9(6):324-332. https://doi.org/10.1111/j.1527-5299.2003.03269.x
Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Current Opinion in Ophthalmology. 2004;15(2):132-135. https://doi.org/10.1097/00055735-200404000-00013
Diestelhorst M, Larsson L-I. A 12-Week, Randomized, Double-Masked, Multicenter Study of the Fixed Combination of Latanoprost and Timolol in the Evening versus the Individual Components. Ophthalmology. 2006;113(1):70-76. https://doi.org/10.1016/j.ophtha.2005.06.027
Kiseleva OA, Bessmertnyi AM. Domestic experience of prescription of fixed combination of latanoprost and timolol maleate in POAG. RMZh. Klinicheskaya oftal’mologiya. 2015;16(3):149-150. (In Russ.).
Radcliffe N. The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies. Clin Ophthalmol. 2014;8:2541-2549. https://doi.org/10.2147/OPTH.S76053
Hartleben C, Ayala M, Chaves—Ayala R et al. Morning vs evening use of Xalacom for primary open glaucoma. In: Book of abstracts World Glaucoma Congress. Vienna; 2005;159.
Martines A, Sanchez M. A four week prospective, randomized, evaluator—masked study of Latanoprost/Timolol compared to Bimatoprost/ Timolol fixed combinations in patients with POAG. In: Book of abstracts 6th Glaucoma symposium. Athens; 2007;127.
Takmaz T, Aşik S, Kürkçüoğlu P, Gurdal C, Can I. Comparison of intraocular pressure lowering effect of once daily morning vs evening dosing of latanoprost/timolol maleate combination. Eur J Ophthalmol. 2008;18(1):60-65. https://doi.org/10.1177/112067210801800110
Ozkurt YB, Sengor T, Evciman T, Haboglu M, Bas G, Aydin S. Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg. Clin Ophthalmol. 2009;3:337-339. https://doi.org/10.2147/opth.s5128.
Alm A, Grunden JW, Kwok KK. Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension. J Glaucoma. 2011;20(4):215-222. https://doi.org/10.1097/IJG.0b013e3181e08121
Astakhov YuS, Goziev SJ, Shikhaliev DJ. The influence of unfixed and fixed combination of Timolol 0.5 % and Latanoprost 0.005 % on local and systemic hemodynamics in treatment of patients with POAG. Oftal’mologicheskie vedomosti. 2009;2(1):12-17. (In Russ.).
Miglior S, Grunden J, Kwok K et al. Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide/timolol in open-angle glaucoma or ocular hypertension. Eye. 2010;24(7):1234-1242. https://doi.org/10.1038/eye.2009.307
He M, Wang W, Huang W. Efficacy and tolerability of the fixed combinations latanoprost/ timolol versus dorzolamide/ timolol in patients with elevated intraocular pressure: a meta-analysis of randomized controlled trials. PLOS one. 2013;8(12):e83606. https://doi.org/10.1371/journal.pone.0083606
Fuma S, Shimazawa M, Imamura T, Kanno Y, Takano N, Tsuruma K, Hara H. Neuroprotective Effect of Ocular Hypotensive Drugs: Latanoprost/ Timolol in Combination Are More Effective than Each as Monotherapy in RGC-5. Biol Pharm Bull. 2016;39(2):192-198. https://doi.org/0.1248/bpb.b15-00584
Instrukciya po medicinskomu primeneniyu lekarstvennogo preparata Ksalakom P N013924/01. (In Russ.).
Inoue K, Fujimoto T, Higa R, et al.Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eye drops from latanoprost 0.005% monotherapy. Clin Ophthalmol. 2012;6:771-775.
Hamacher T, Schinzel M, Schölzel-Klatt A, et al., Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies, British Journal of Ophthalmology. 2004;88:1295-1298.

Close metadata